Cancer Research at Children's Hospital

In 1970, a child diagnosed with leukemia had a very slim chance of survival. Today, the most common type of leukemia has a cure rate of 70 to 90 percent.

The reason? Research.

Children’s Hospital of Pittsburgh of UPMC has been a member of the Children’s Oncology Group (COG) — a multi-institutional pediatric cancer research organization sponsored by the National Cancer Institute — since 1961.

The COG consists of experts from around the country who are dedicated to improving the knowledge and treatment of childhood cancer. Membership in this prestigious organization allows us to offer state-of-the-art therapy to children with all forms of childhood cancers.

Oncology Research Projects at Children's Hospital

With support from the COG, doctors and researchers from the Hematology/Oncology Division are conducting world-renowned research to:

  • Learn why some children develop cancers.
  • Create innovative cancer treatments.
  • Find cures for childhood cancers.

Several Hematology/Oncology physician-scientists also receive funding support from the National Institutes of Health (NIH). The NIH is the federal agency that conducts, supports, and coordinates biomedical research in the United States.

Ongoing oncology research projects at Children's Hospital include studies of:

  • Critical biochemical events that control the growth, maturation, and death of cells that cause leukemia.
  • A family of genes that cause cancers such as Burkitt’s lymphoma and neuroblastoma.
  • Graft-versus-host disease following unrelated donor stem cell transplantation.
  • Various treatment options for pediatric blood disorders such as severe aplastic anemia and sickle cell disease.

For more details on active research projects, see Dr. Edward Prochownik's physician profile.

Clinical Studies

Acute Lymphoblastic Leukemia and B-Lineage Lymphoma Treatment via Risk-Adapted Chemotherapy – Phase III

Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk B-Acute Lymphoblastic Leukemia or localized B-Lineage Lymphoblastic Lymphoma

Read more

Acute Lymphoblastic Leukemia Cell Banking Study

Proper Protocols for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Read more

Acute Myeloid Leukemia trial using Bortezomib and Sorafenib – Phase III

Trial for Patients with de novo Acute Myeloid Leukemia using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD

Read more

Acute Promyelocytic Leukemia Treatment using Arsenic Trioxide and All Trans-Retinoic Acid – Phase III

Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia using Arsenic Trioxide and All Trans-Retinoic Acid

Read more

Anaplastic Large Cell Lymphoma Treatment with Brentuximab Vedotin or Crizotinib – Phase II

Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma

Read more

Brain Tumor Memory Study – Phase II

Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Read more

Central Nervous System Germ Cell Tumor Treatment with Chemotherapy and Radiation – Phase II

Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors

Read more

Central Nervous System Tumor Treatment with PD-0332991 – Phase I

A Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors

Read more

Craniopharyngioma Treatment with PEGIntron – Phase II

Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma

Read more

DIPG Treatment with MK-1775 and Local Radiation – Phase I

MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Read more

Ependymoma Treatment with Maintenance Chemotherapy – Phase III

Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma

Read more

Ependymoma Vaccine Trial – Pilot

Treatment for Recurrent Ependymomas in Children Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod

Read more

Ewing Sarcoma Tissue Banking Study

A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens

Read more

Ewing Sarcoma Treatment with Combination Chemotherapy Including Ganitumab – Phase II

Adding the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Read more

Ewing Sarcoma Treatment with Combination Chemotherapy Including Topotecan – Phase III

Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

Read more

Gliomas (Low-Grade) Vaccine Study – Phase II

Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)

Read more

Glioma Treatment with Selumetinib (AZD6244) – Phase II

Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Read more

Glioma Treatment with Veliparib, Radiation and Temozolomide – Phase I/II

ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas

Read more

Gliomas Vaccine Study – Pilot

Treatment of Newly Diagnosed Brainstem Gliomas and Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade and High-Grade Gliomas

Read more

High-Risk Acute Lymphoblastic Leukemia Treatment with Combination Chemotherapy – Phase III

Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia, Testing Clofarabine in the Very High Risk Stratum

Read more

High-Risk Medulloblastoma Treatment with Chemotherapy and Radiation – Phase III

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Read more

Hodgkin Lymphoma Treatment with Brentuximab Vedotin – Phase III

Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents

Read more

Hodgkin Lymphoma Treatment with Brentuximab Vendotin and Gemcitabine – Phase I/II

Brentuximab Vedotin in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma

Read more

Medulloblastoma and PNET Therapies with Temozolomide, Irinotecan, and Bevacizumab – Phase II

Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

Read more

Medulloblastoma Treatment with Carboplatin and Isotretinoin – Phase III

Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Read more

M0 Medulloblastoma Treatment in Very Young Children – Phase I

Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas

Read more

M0 Medulloblastoma Treatment in Young Children – Phase II

Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age

Read more

Non-Hodgkin Lymphoma or B-Cell Leukemia Evaluation of Rituximab– Phase II/III

Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma or Mature B-cell Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Read more

Osteosarcoma Response to Dinutiximab and Sargramostim – Phase II

Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab) in Combination with GM-CSF (Sargramostim) in Patients with Recurrent Osteosarcoma

Read more

Osteosarcoma Tissue Banking Study

A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens

Read more

Pediatric Tumors and Specimen Study

A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors

Read more

Pilocytic Astrocytoma and Optic Pathway Glioma Treatment with Lenalidomide – Phase II

Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Read more

Plexiform Neurofibromas Treatment with PEG-Intron - Phase II

Peginterferon alfa-2b in Treating Young Patients with Unresectable, Sympotomatic or Life-Threatening Plexiform Neurofibromas Associated with Neurofibromatosis Type 1

Read more

Sickle Cell Acute Chest Syndrome Treatment with Prasugrel – Phase III

A Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

Read more

Sickle Cell Disease Treatment with BMT and Conditioning (STRIDE) – Phase II

A Study of Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease

Read more

Sickle Cell Medication Management Study

Patient-Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy with Hydroxyurea in Patients with Sickle Cell Disease

Read more

Sickle Cell Pain Crisis Management Study (SUSTAIN) – Phase II

Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises (SUSTAIN)

Read more

Sickle Cell Vaso-Occlusive Pain Crisis Treatment Study (EPIC) – Phase II

Evaluation of Purified Poloxamer 188 (MST 188) in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

Read more

Soft Tissue Sarcoma Treatment with Preoperative Radiation and Pazopanib (PAZNTIS Trial) – Phase II/III

Pazopanib Neoadjuvunt Trial on Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib

Read more

Solid Tumor and Lymphoma Treatment with PF-02341066 – Phases I and II

PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Read more

Solid Tumor or ALCL Treatment with Crizotinib and Conventional Chemotherapy – Phase I

Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Read more

Solid Tumor Treatment with MK-1775 – Phase I/II

MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

Read more

Solid Tumor Treatment with Ramucirumab – Phase I

A Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

Read more

T-cell Lymphoblastic Leukemia and Lymphoma Treatment with Bortezomib – Phase III

Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Read more

Transient Myeloproliferative Disorder Blood Study

Biology Study of Transient Myeloproliferative Disorder in Children with Down Syndrome

Read more

Tumor and Acute Lymphoblastic Leukemia Treatment with BMN 673 and Temozolomide – Phase I/II

BMN 673, an Oral Poly Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

Read more

Tumor Treatment with Nivolumab with and without Ipilimumab – Phase I/II

Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Read more

Wilms Tumor Treatment with Combination Chemotherapy and Surgery – Phase III

Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

Read more